Cart
sales@molnova.com
EC330
CAS No. 2016795-77-8
EC330 ( —— )
Catalog No. M20728 CAS No. 2016795-77-8
EC330 a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 222 | In Stock |
|
| 10MG | 317 | In Stock |
|
| 25MG | 536 | In Stock |
|
| 50MG | 763 | In Stock |
|
| 100MG | 1053 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameEC330
-
NoteResearch use only not for human use.
-
Brief DescriptionEC330 a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range.
-
DescriptionEC330 a novel steroidal LIF inhibitor showed cytotoxicity in various cancer cell lines and NCI-60 cell line panel at low nano-molar range.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorLIF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2016795-77-8
-
Formula Weight462.57
-
Molecular FormulaC30H32F2O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:20 mg/mL (43.24 mM)
-
SMILES[H][C@@]12CC[C@@](O)(C(F)(F)C#C)[C@@]1(C)C[C@H](c1ccc(cc1)C1CC1)C1=C3CCC(=O)C=C3CC[C@@]21[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nair H B Santhamma B Viswanadhapa S et al. Abstract LB-208: First-in-class steroidal leukemia inhibitory factor (LIF) inhibitor in targeted cancer therapy[J]. Cancer Research 2016 76(14 Supplement):LB-208-LB-208.
molnova catalog
related products
-
Dabcyl acid
Dabcyl acid is the original dark fluorescence quencher.
-
DSP-4 hydrochloride
DSP-4 hydrochloride (Neurotoxin DSP 4 hydrochloride) can be used for the temporary selective degradation of the central and peripheral noradrenergic neurons, mainly those from the locus coeruleus (LC).
-
SJ6986
SJ6986 is a chemical probe for studying the role of GSPT1/2 in vitro and in vivo. SJ6986 supports the utility of a diverse library of CRBN binders in the pursuit of targeting undruggable oncoproteins.
